Recent preclinical work supports combining B4GALT1 inhibition with immunotherapy: in a lung adenocarcinoma model, genetic or pharmacological inhibition of B4GALT1 enhanced CD8+ T-cell infiltration and synergized with anti–PD-1 therapy. The gene discussed is CD8A; the disease is lung adenocarcinoma.